BioLineRX
BLRX
24 hedge funds and large institutions have $13.9M invested in BioLineRX in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0% less ownership
Funds ownership: 0.04% → 0.04% (-0%)
15% less capital invested
Capital invested by funds: $16.3M → $13.9M (-$2.42M)
23% less funds holding
Funds holding: 31 → 24 (-7)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$179K |
| 2 |
DG
Delek Group
Herzliya,
Israel
|
+$59.7K |
| 3 |
NFG
Next Financial Group
Houston,
Texas
|
+$12.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.8K |
| 5 |
DWM
Doyle Wealth Management
St. Petersburg,
Florida
|
+$1.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$157K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$33K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$16K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$14K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EMG
26
ETF Managers Group
Summit,
New Jersey
| – | -$157K | -607 | Closed |
|
|
27
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$33K | -128 | Closed |
|
|
SM
28
Sabby Management
Miami Beach,
Florida
| – | -$16K | -62 | Closed |
|
|
29
Citadel Advisors
Miami,
Florida
| – | -$14K | -56 | Closed |
|
|
VF
30
Virtu Financial
New York
| – | -$5K | -21 | Closed |
|
|
31
UBS Group
Zurich,
Switzerland
| – | -$5K | -20 | Closed |
|
|
PVH
32
Psagot Value Holdings
Tel Aviv,
Israel
| – | -$3K | -11 | Closed |
|
BLRX Hedge Fund Activity: Q2 2019 in Review
24 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2019, worth a combined $13.9M — down 15% from $16.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BLRX and 1 opened new positions — a net loss of 6 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Morgan Stanley, adding an estimated $179K. The largest seller was ETF Managers Group, exiting entirely with an estimated $157K sold.
- 24 institutional investors held BioLineRX (BLRX) as of Q2 2019, down from 31 in Q1 2019.
- Funds reported $13.9M of BioLineRX stock for Q2 2019, down 15% quarter-over-quarter.
- 1 fund opened new BioLineRX positions in Q2 2019 and 7 closed out, a net change of -6 holders.
- The largest BioLineRX buyer in Q2 2019 was Morgan Stanley, an estimated $179K added.
- The largest BioLineRX seller in Q2 2019 was ETF Managers Group, an estimated $157K sold.
Based on aggregated 13F filings for Q2 2019.